What happened
Chong Kun Dang Pharmaceutical filed provisional (unaudited) separate results for Q2 2026: revenue of US$335M (+10.7% year on year), operating profit of US$14M (−10.1% year on year) and net income of US$12.7M (−7.6% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$335M |
|---|---|
| Revenue vs a year earlier | +10.7% |
| Operating profit | US$14M |
| Net income | US$12.7M |
| Period | Q2 2026 (separate) |
| Filed | 2026-07-31, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260731800724 → open original filing |
Source: DART. Information only, not investment advice.